CC-90009 clinical trials
Also written CC-90009.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses CC-90009 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CC-90009
- 3
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CC-90009 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic SyndromesTerminatedPhase 1CelgeneNCT02848001Written as CC-90009
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid LeukemiaTerminatedPhase 1CelgeneNCT04336982Written as CC-90009
- A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male SubjectsCompletedPhase 1CelgeneNCT04297124Written as CC-90009